Government Agencies FDA

  • pfizer_logo_new_200.jpg

    Newly released documents reveal that Pfizer presented a study falsely claiming that its arthritis drug, Celebrex, was safer on the stomach than competing drugs, the New York Times reports. 

  • factory-worker2-200.jpg

    U.S. regulators, retailers and manufacturers are growing increasingly concerned that a surge in the number of products being recalled is resulting in "fatigue" by the public — increasing the chance that consumers could ignore or miss a recall that could ultimately endanger their health, USA Today reports.

  • Onyx Pharma CEO on New Cancer Drug

    Anthony Coles, Onyx Pharmaceuticals president/CEO, discusses the status of his company's latest drugs.

  • salmon_whole_fish_200.jpg

    If Americans ever eat genetically engineered fast-growing salmon, it might be because of a Soviet biologist turned oligarch turned government minister turned fish farming entrepreneur, the New York Times reports.

  • Jefferies Upgrades Arena Pharmaceuticals to 'Buy'

    CNBC's Seema Mody reports on the latest details of the FDA advisory panel's review of Arena Pharmaceuticals' anti-obesity drug.

  • DMAA

    Ten days after the FDA sent warning letters to manufacturers of supplements with DMAA in it, the nation’s largest supplement retailers still have the product on the shelves.

  • DMAA

    In a wake of a warning letter sent to them by the FDA, some companies whose pre-workout or weight loss products include the ingredient DMAA, are starting to move on with life without it.

  • A warning letter written by the Food & Drug Administration last week to ten companies that produce pre-workout supplements with the ingredient dimethylamyamine (DMAA) has sent shockwaves through the industry, not only to the producers of the products but to consumers who have taken them.

  • Supplement Stir: DMAA

    CNBC's Darren Rovell reports on how shares of GNC Holdings and Vitamin Shoppe are holding up since Amazon.com announced they will be pulling products containing DMAA.

  • Amazon.com Pulling DMAA Products

    CNBC's Darren Rovell reports Amazon.com is pulling all products containing DMAA, an ingredient the FDA stated does not derive from a plant.

  • Eli Lilly's CEO on Prescription for Profits

    John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.

  • NYSE traders

    U.S. securities regulators on Wednesday finalized long-awaited rules that will dictate which companies dealing in derivatives will be subject to costly capital, margin and business conduct requirements.

  • Alzheimer Early Detection & the FDA

    CNBC's Seema Mody reports on a major development in the early detection of Alzheimer's disease, and discussing how the FDA approved brain scan from Eli Lilly works, with Robert Petersen, M.D., Mayo Clinic.

  • burger_king_logo_new.jpg

    Sharpen your pencils, it's Last Call quiz time.

  • Marlboro Cigarettes

    A federal requirement would have begun forcing U.S. tobacco companies to put large graphic images on their cigarette packages, until a judge blocked the ruling Wednesday. 

  • Vivus CEO Leland Wilson saw “a very powerful signal” that anti-obesity drug Qnexa would be approved.

  • Vivus CEO Expects FDA Approval in April

    Leland Wilson, Vivus CEO, discusses the optimist outlook for his company after an FDA panel backed its new diet drug, Qnexa; marketing strategies for the new product; and whether his company is now a potential takeover target, with the Fast Money traders.

  • mm_avatar_100_cramer.jpg

    Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.

  • Can Drugs Fight Obesity? FDA Weighs In

    There will be no silver bullet to reduce obesity, says Margaret Hamburg, FDA commissioner. Adding that, "generic drugs make a huge difference in patient care."

  • Margaret Hamburg, MD and Commissioner of FDA

    Generic drugs are in focus at Generic Pharmaceutical Association's annual meeting in Orlando, Florida. The hot button issue: backlog of generic drug applications at the Food & Drug Administration.